A Phase 1 Study of Convection-Enhanced Delivery of Intraputaminal AAV2-GDNF in Advanced Parkinson's Disease.
BACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disorder. RESULTS: Across follow-up, 562 adverse events were recorded; 45 were considered possibly or probably related to the study drug.
BACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disorder. RESULTS: Across follow-up, 562 adverse events were recorded; 45 were considered possibly or probably related to the study drug.
What the study was
- Study design
- Phase 1 clinical trial
- Category
- Drug Development
- Maturity
- Validated
- Journal
- Movement disorders : official journal of the Movement Disorder Society
Why it surfaced
Relevant Rare diseases with high unmet need study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.